CHMP recommends drug for relapsed/refractory cHL

Pembrolizumab (Keytruda)
Photo courtesy of Merck
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the anti-PD-1 therapy pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The recommendation pertains specifically to adults with cHL who have... [Read Article]

Most blood cancer mutations due to DNA replication errors

DNA helices
Image courtesy of the
National Institute of
General Medical Sciences
A new study supports the idea that most cancer-driving mutations are a result of DNA replication errors, not heredity or lifestyle/environmental factors. For all 32 cancer types studied, researchers found that 66% of driver mutations resulted from DNA replication errors,... [Read Article]

New resource designed to help prevent CINV

Cancer patient
receiving chemotherapy
Photo by Rhoda Baer
The Hematology/Oncology Pharmacy Association (HOPA) has announced the release of a toolkit intended to help prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients. The Time to Talk CINV™ toolkit was designed to facilitate dialogue between patients and their healthcare teams to ensure no... [Read Article]